

114TH CONGRESS  
2D SESSION

# H. R. 5956

To amend the Public Health Service Act to better address substance use and substance use disorders among young people.

---

## IN THE HOUSE OF REPRESENTATIVES

SEPTEMBER 8, 2016

Ms. CLARK of Massachusetts (for herself and Mr. BUCSHON) introduced the following bill; which was referred to the Committee on Energy and Commerce

---

## A BILL

To amend the Public Health Service Act to better address substance use and substance use disorders among young people.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Youth Opioid Use  
5 Treatment Help Act of 2016” or the “YOUTH Act”.

6 **SEC. 2. REAUTHORIZATION OF SUBSTANCE ABUSE TREAT-**  
7 **MENT SERVICES FOR CHILDREN AND ADO-**  
8 **LESCENTS.**

9 (a) IN GENERAL.—Section 514 of the Public Health  
10 Service Act (42 U.S.C. 290bb–7) is amended—

1 (1) by striking “abuse” and inserting “use”  
2 each place it appears;

3 (2) by striking “children and adolescents” and  
4 inserting “children, adolescents, and young adults”  
5 each place it appears; and

6 (3) in subsection (f), by striking “for fiscal  
7 years 2002 and 2003” and inserting “for each of  
8 fiscal years 2017 through 2022”.

9 (b) TECHNICAL CORRECTION.—Section 514 of the  
10 Public Health Service Act (42 U.S.C. 290bb–9), as added  
11 by section 3632 of the Methamphetamine Anti-Prolifera-  
12 tion Act of 2000 (Public Law 106–310; 114 Stat. 1236),  
13 is redesignated as section 514B.

14 **SEC. 3. ACCESS TO MEDICATION-ASSISTED TREATMENT**  
15 **FOR ADOLESCENTS AND YOUNG ADULTS**  
16 **DEMONSTRATION PROGRAM.**

17 (a) IN GENERAL.—The Secretary of Health and  
18 Human Services, acting through the Director of the Agen-  
19 cy for Healthcare Research and Quality (in this section  
20 referred to as the “Director”), shall award grants to eligi-  
21 ble entities to establish demonstration programs to—

22 (1) expand access to medication-assisted treat-  
23 ment for opioid use disorders among adolescents and  
24 young adults;

1           (2) identify and test solutions to overcoming  
2           barriers to implementation of medication-assisted  
3           treatment for adolescents and young adults; or

4           (3) create and distribute for pediatric health  
5           care providers resources on medication-assisted  
6           treatment training and implementation.

7           (b) ELIGIBLE ENTITIES.—To be eligible to receive a  
8           grant under subsection (a), an entity shall—

9           (1) be a State, political subdivision of a State,  
10          Indian tribe, tribal organization, professional pedi-  
11          atric provider organization, professional addiction  
12          medicine provider, hospital, an institution of higher  
13          education, or other appropriate public or nonprofit  
14          institution; and

15          (2) certify that it is in compliance with all ap-  
16          plicable registration and licensing requirements.

17          (c) APPLICATION.—To seek a grant under this sec-  
18          tion, an entity shall submit to the Director an application  
19          at such time, in such manner, and containing such infor-  
20          mation as the Director may require.

21          (d) DURATION.—An eligible entity may receive funds  
22          under this section to carry out a demonstration program  
23          described in this section for a period of not greater than  
24          3 years. After the first year for which funding is provided  
25          to an eligible entity for a demonstration program, funding

1 may be provided under this section for a subsequent year  
2 for such program only upon review of such program by  
3 the Director and approval by the Director of such subse-  
4 quent year of funding.

5 (e) REPORTS.—

6 (1) BY GRANT RECIPIENTS.—Each eligible enti-  
7 ty awarded a grant under this section for a dem-  
8 onstration program shall submit to the Director  
9 progress reports on such demonstration program at  
10 such times, in such manner, and containing such in-  
11 formation as the Director may require.

12 (2) BY DIRECTOR.—Not later than one year  
13 after the date on which all demonstration programs  
14 funded under this section have been completed, the  
15 Director shall submit to the Committee on Health,  
16 Education, Labor, and Pensions of the Senate, and  
17 the Committee on Energy and Commerce of the  
18 House of Representatives a report that—

19 (A) describes the availability of medication-  
20 assisted treatment for adolescents and young  
21 adults with opioid use disorders in the United  
22 States, including barriers to such treatment;

23 (B) describes the specific demonstration  
24 programs carried out pursuant to this section;

1 (C) evaluates the effectiveness of such pro-  
2 grams;

3 (D) evaluates any unintended consequences  
4 of such programs; and

5 (E) provides recommendations for ensuring  
6 that medication-assisted treatment is accessible  
7 to adolescents and young adults with opioid use  
8 disorders.

9 (f) DEFINITIONS.—In this section:

10 (1) The phrase “adolescents and young adults”  
11 means individuals who have attained 10 years of age  
12 and not yet attained 26 years of age.

13 (2) The term “medication-assisted treatment”  
14 means pharmacological treatments approved by the  
15 Food and Drug Administration, in combination with  
16 counseling and behavioral therapies.

17 (3) The term “opioid use disorder” means a  
18 substance use disorder that is a problematic pattern  
19 of opioid use leading to clinically significant impair-  
20 ment or distress occurring within a 12-month period.

21 (4) The term “pediatric health care provider”  
22 means a provider of health care to individuals who  
23 have attained 10 years of age and not yet attained  
24 26 years of age.

1           (5) The term “professional pediatric provider  
2           organization” means a national organization whose  
3           members consist primarily of pediatric health care  
4           providers.

5           (g) AUTHORIZATION OF APPROPRIATIONS.—There is  
6           authorized to be appropriated \$5,000,000 to carry out this  
7           section.

8           **SEC. 4. GAO STUDY AND REPORT ON PROGRAMS AND RE-**  
9                           **SEARCH RELATIVE TO SUBSTANCE USE AND**  
10                          **SUBSTANCE USE DISORDERS AMONG ADO-**  
11                          **LESCENTS AND YOUNG ADULTS.**

12           (a) STUDY.—The Comptroller General of the United  
13           States shall conduct a study on how Federal agencies are  
14           addressing prevention of, treatment for, and recovery from  
15           substance use by and substance use disorders among ado-  
16           lescents and young adults. Such study shall include an  
17           analysis of each of the following:

18                   (1) The research that has been, and is being,  
19                   conducted or supported by the Federal Government  
20                   on prevention of, treatment for, and recovery from  
21                   substance use by and substance use disorders among  
22                   adolescents and young adults, including an assess-  
23                   ment of—

24                           (A) such research relative to any unique  
25                   circumstances (including social and biological

1           circumstances) of adolescents and young adults  
2           that may make adolescent-specific and young  
3           adult-specific treatment protocols necessary, in-  
4           cluding any effects that substance use and sub-  
5           stance use disorders may have on brain develop-  
6           ment and the implications for treatment and re-  
7           covery; and

8                   (B) areas of such research in which great-  
9                   er investment or focus is necessary relative to  
10                  other areas of such research.

11           (2) The Federal non-research programs and ac-  
12           tivities that address prevention of, treatment for,  
13           and recovery from substance use by and substance  
14           use disorders among adolescents and young adults,  
15           including an assessment of the effectiveness of such  
16           programs and activities in preventing substance use  
17           by and substance use disorders among adolescents  
18           and young adults, treating such adolescents and  
19           young adults in a way that accounts for any unique  
20           circumstances faced by adolescents and young  
21           adults, and supports long-term recovery among ado-  
22           lescents and young adults.

23           (3) Gaps that have been identified by Federal  
24           officials and experts in Federal efforts relating to  
25           prevention of, treatment for, and recovery from sub-

1       stance use by and substance use disorders among  
2       adolescents and young adults, including gaps in re-  
3       search, data collection, and measures to evaluate the  
4       effectiveness of Federal efforts, and the reasons for  
5       such gaps.

6       (b) REPORT.—Not later than 2 years after the date  
7       of enactment of this Act, the Comptroller General shall  
8       submit to the appropriate committees of the Congress a  
9       report containing the results of the study conducted under  
10      subsection (a), including—

- 11               (1) a summary of the findings of the study; and  
12               (2) recommendations based on the results of  
13      the study, including recommendations for such areas  
14      of research and legislative and administrative action  
15      as the Comptroller General determines appropriate.

○